<DOC>
	<DOCNO>NCT01153269</DOCNO>
	<brief_summary>The aim study observe tolerability effectiveness Kaletra Human Immunodeficiency Virus/Hepatitis-B Virus Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patient .</brief_summary>
	<brief_title>Long-term Effectiveness Safety Hepatitis-co-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Patients infect HIV1 HBV HCV Age â‰¥18 year Patients initiate LPV/r contain antiretroviral ( ARV ) regimen Contraindications describe SmPC ( summary product characteristic ) time prescription</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Co-infection Hepatitis B Hepatitis C</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Effectiveness</keyword>
</DOC>